• Leukemias, lymphomas, and other hematologic cancers

Zolinza Generic Name & Formulations

General Description

Vorinostat 100mg; caps.

Pharmacological Class

Histone deacetylase inhibitor.

How Supplied



Zolinza Indications


Refractory cutaneous T-cell lymphoma.

Zolinza Dosage and Administration


Take with food. Swallow whole. 400mg once daily. If not tolerated, may reduce to 300mg once daily, then to 300mg once daily 5 days/week if needed. Continue until disease progression or not tolerated.


<18yrs: not established.

Zolinza Contraindications

Not Applicable

Zolinza Boxed Warnings

Not Applicable

Zolinza Warnings/Precautions


Prior history of thromboembolism; monitor for DVT, PE. Correct electrolyte disturbances before starting therapy. Maintain adequate hydration. Diabetes. Monitor CBC, platelets, blood glucose, serum creatinine, electrolytes (esp. potassium, calcium, magnesium) every 2 weeks for 1st 2 months, then monthly. Hepatic impairment. Embryo-fetal toxicity. Pregnancy: exclude status within 7 days prior to initiation. Use effective contraception during and for ≥6months (females) or ≥3months (males w. female partners) after the last dose. Nursing mothers: not recommended (during and for ≥1week after the last dose).

Zolinza Pharmacokinetics

See Literature

Zolinza Interactions


Increased risk of thrombocytopenia and GI bleed with other HDAC inhibitors (eg, valproic acid); monitor. Concomitant warfarin: monitor PT, INR frequently.

Zolinza Adverse Reactions

Adverse Reactions

GI symptoms (eg, diarrhea, nausea, anorexia, weight decrease, vomiting, constipation), fatigue, chills, thrombocytopenia, anemia (may need to modify dose or discontinue), dysgeusia, dry mouth; PE, DVT, hyperglycemia.

Zolinza Clinical Trials

See Literature

Zolinza Note

Not Applicable

Zolinza Patient Counseling

See Literature